OTTAWA, Nov. 29, 2017 /CNW/ - Annidis Corporation
(TSX Venture: RHA) ("Annidis" or the Company") announces that it
has granted an aggregate of 5,120,000 options to employees and
consultants of the Corporation. Each option entitles the holder to
acquire one common share in the capital of the Corporation at an
exercise price of $0.025. These
options will expire on November 28,
2022.
About Annidis Corporation
Annidis (TSX-V: RHA) develops and markets imaging technologies
to eye care professionals. It is a North American based company
founded on scientific concepts emerging from a decade of research
and development by the Annidis team in consultation with respected
eye care professionals in Canada,
the United States and China. The Annidis RHA™ is a
non-invasive ocular pathology management system that integrates
advanced multi-spectral imaging with analytic software for early
detection and management of ocular pathologies such as glaucoma,
age-related macular degeneration, and diabetic retinopathy. The
Company distributes its systems in Canada, United
States and, through a distributor and major shareholder, in
China.
This news release may contain "forward-looking information"
within the meaning of applicable Canadian securities
legislation. Statements made in this news release, other than
those concerning historical financial information, may be
forward-looking and therefore subject to various risks and
uncertainties. The words "may", "will", "could", "should",
"would", "suspect", "outlook", "believe", "plan", "anticipate",
"estimate", "expect", "intend", "forecast", "objective", "hope",
and "continue" (or the negative thereof), and words and expressions
of similar import are intended to identify forward-looking
statements. Certain material factors or assumptions are
implied in making forward-looking statements and actual results may
differ materially from those expressed or implied in such
statements. Factors that could cause results to vary include
those identified in the Corporation's filings with Canadian
securities regulatory authorities, as well as the applicability of
patents and proprietary technology; the outcome of pending
corporate transactions; possible patent ligation; regulatory
approval of products in development; changes in government
regulation or regulatory approval processes; government and third
party reimbursement; dependence on strategic partnerships;
intensifying competition; rapid technological change in the
industry; anticipated future losses; the ability to access capital;
and the ability to attract and retain key personnel. All
forward-looking information presented herein should be considered
in conjunction with such filings. Except as required by
Canadian securities laws, the Corporation does not undertake to
update any forward-looking statements; such statements speak only
as of the date made.
Neither TSX Venture Exchange nor its Regulation Services
Provider (as that term is defined in the policies of the TSX
Venture Exchange) accepts responsibility for the adequacy or
accuracy of this release.
SOURCE Annidis Corporation